The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Dear E.M.: Obstructive sleep apnea is when a person stops breathing during sleep due to obstruction of their airway. Some ...

Dr. Roach: I’m a 67-year-old female in pretty good health. The only medications I take are for my thyroid, arthritis and ...

Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.